Leonardo Tjahjono, MD, FAAD

Twelve years of inconsistent care have left this patient reluctant to even be in the room. The panel sets short- and long-term goals for HS.

Choosing between TNF and IL-17 inhibition is only part of the picture. The panel maps out comorbidity screening, pain management, and where cannabis fits in.

This patient hasn't reached Hurley Stage 3, but her quality of life already has. The panel makes the case for escalating therapy well before anatomic damage sets in.

A five-year history of 'ingrown hairs' turns out to be HS. The panel explores why primary care so often misses this diagnosis, and how to rebuild trust once it's finally named.

New IL-17 inhibitors are changing first-line choices for adolescent and adult HS alike. The panel weighs efficacy benchmarks against follow-up strategy and comorbidity screening.

Parents often hear 'biologic' and imagine the worst. The panel explains how they build trust, set expectations, and time that first injection.

Examining a teenager's groin or axilla requires more than clinical skill. The panel discusses consent, comfort, and why HS diagnosis still lags for years.

A 17-year-old with painful, recurrent nodules has quietly given up gym class, social events, and her school prom. The panel walks through what her case demands.

Hurley staging built the field's first common language for HS, but the panel explains why it falls short and what newer scoring tools capture instead.

A decade after the first dedicated therapy arrived, the panel reflects on how far HS recognition and treatment have come, and how far they still need to go.

In a patient with longstanding Hailey-Hailey disease, lebrikizumab was associated with rapid improvement in symptoms and quality of life.